Table 4.
Monocyte subsets and expression of different functional molecules before cART initiation.
| LR-subjects (13) | HR-subjects (15) | p | Univariate AnalysisOR (CI); p | Bivariate AnalysisOR (CI); p | |
|---|---|---|---|---|---|
| % Classical monocytes | 79.6 [65.6–88.1] | 69.7 [62.0–84.9] | 0.3 | 1.03 (0.98–1.03); 0.2 | 1.03 (0.97–1.09); 0.4 |
| MFI CD11b | 2,189 [1,910–2,469] | 1,521 [1,228–2,399] | 0.134 | 1.01 (1.00–1.00); 0.094 | 1.01 (1.00–1.00); 0.118 |
| % CCR2 | 82.8 [74.4–90.8] | 84.2 [78.2–89.9] | 0.9 | 0.98 (0.93–1.05); 0.6 | 0.97 (0.90–1.0); 0.3 |
| % β7 | 9.1 [4.1–26.2] | 16.7 [2.6–26.9] | 0.9 | 0.99 (0.96–1.03); 0.6 | 0.98 (0.94–1.02); 0.3 |
| % IDO | 1.4 [0.6–3.4] | 1.0 [0.7–4.6] | 0.9 | 1.05 (0.83–1.22); 0.9 | 0.98 (0.98–1.20); 0.8 |
| % PDL1 | 23.9 [12.3–42.3] | 13.7 [7.0–31.6] | 0.062 | 1.04 (0.99–0.11); 0.114 | 1.03 (0.99–1.08); 0.163 |
| % Intermediate monocytes | 10.8 [6.6–13.7] | 15.4 [9.1–26.1] | 0.3 | 0.97 (0.91–1.04); 0.4 | 0.97 (0.90–1.04); 0.4 |
| MFI CD16 | 1,090 [511–1,607] | 544 [429–845] | 0.088 | 1.02 (1.00–1.00); 0.030 | 1.02 (1.00–1.00); 0.054 |
| MFI CD11b | 2,281 [1,944–3,052] | 2,395 [1,324–2,956] | 0.4 | 1.00 (0.99–1.00); 0.4 | 1.00 (0.99–1.00); 0.4 |
| % CCR2 | 51.9 [44.3–61.4] | 64.8 [45.9–80.0] | 0.189 | 0.97 (0.93–1.02); 0.189 | 0.94 (0.91–1.01); 0.097 |
| % β7 | 9.1 [2.5–16.4] | 6.9 [2.5–24.3] | 0.7 | 0.98 (0.93–1.03); 0.4 | 0.96 (0.91–1.01); 0.123 |
| % IDO | 3.5 [1.0–7.8] | 1.9 [0.7–6.8] | 0.5 | 1.03 (0.92–1.17); 0.6 | 1.02 (0.89–1.15); 0.8 |
| % PDL1 | 47.7 [31.0–69.5] | 37.4 [23.6–58.7] | 0.2 | 1.02 (0.98–1.05); 0.3 | 1.01 (0.98–1.05); 0.5 |
| % Patrolling monocytes | 2.8 [1.9–8.9] | 4.1 [2.4–7.5] | 0.6 | 1.01 (0.86–1.16); 0.9 | 1.09 (0.91–1.31); 0.4 |
| MFI CD16* | 2,372 [1,307–3,253] | 1,248 [872–2,513] | 0.123 | 1.00 (1.00–1.00); 0.3 | 1.00 (1.00–1.01); 0.3 |
| MFI CD11b* | 827 [612–1,029] | 734 [512–1,007] | 0.6 | 1.00 (0.99–1.00); 0.8 | 0.99 (0.99–1.00); 0.4 |
| % CCR2* | 9.6 [6.2–15.9] | 20.6 [10.4–30.6] | 0.072 | 0.98 (0.94–1.02); 0.3 | 0.97 (0.93–1.02); 0.189 |
| % β7* | 5.4 [4.1–10.4] | 8.8 [4.9–27.3] | 0.2 | 0.96 (0.90–1.02); 0.2 | 0.94 (0.88–1.01); 0.079 |
| % IDO* | 0.4 [0.1–1.4] | 0.5 [0.3–1.4] | 0.7 | 1.08 (0.74–1.59); 0.7 | 1.04 (0.70–1.53); 0.9 |
| % PDL1* | 69.3 [42.9–83.9] | 46.5 [25.6–64.9] | 0.051 | 1.04 (0.99–1.08); 0.069 | 1.03 (0.99–1.08); 0.166 |
| % Shedding monocytes | 4.3 [2.5–5.2] | 5.9 [3.7–9.9] | 0.072 | 0.69 (0.48–1.01); 0.058 | 0.71 (0.48–1.05); 0.088 |
Variables are expressed as median and interquartile range [IQR]. p, Mann–Whitney U test was used for comparisons. A bivariate regression was performed in order to adjust by CD4 T-cell counts at cART initiation. Results were expressed as odds ratios (ORs) and 95% confidence intervals (CIs). *Comparisons of the expression of molecules were performed in 26 subjects (LR = 12, HR = 14).
Statistically significant values are highlighted in bold, p < 0.005.